<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2206">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550315</url>
  </required_header>
  <id_info>
    <org_study_id>111577</org_study_id>
    <secondary_id>R01HL102387</secondary_id>
    <nct_id>NCT01550315</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Sodium Intake on Vascular Endothelium</brief_title>
  <official_title>A Pilot Study of the Effect of Dietary Sodium Intake on Assessments of Vascular Endothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test the hypothesis that markers of vascular endothelial dysfunction&#xD;
      will be exaggerated acutely with an extreme high sodium diet compared to an extreme&#xD;
      low-sodium diet. The investigators will compare patients with postural orthostatic&#xD;
      tachycardia (POTS) to healthy control subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve a crossover design in which each subject will be assessed (as below)&#xD;
      while on a very low-sodium (10 mEq/day) diet compared with a very high-sodium diet. These&#xD;
      acute dietary interventions will be part of the parent study (&quot;Dietary Salt in Postural&#xD;
      Tachcyardia Syndrome&quot; funded by R01 HL102387) for 4-5 days at the time of the study. Dietary&#xD;
      success will be assessed using a 24h urine for sodium and creatinine as a part of the parent&#xD;
      study.&#xD;
&#xD;
      Blood will be drawn and collected in a fasting state for future assay and analysis of the&#xD;
      following tests:&#xD;
&#xD;
        -  Glucose, Insulin (glucose impairment, insulin resistance)&#xD;
&#xD;
        -  Fasting lipid profile&#xD;
&#xD;
        -  C-Reactive Protein (hsCRP) (inflammatory state)&#xD;
&#xD;
        -  Inflammatory cytokines (inflammatory state)&#xD;
&#xD;
        -  aliquots (future analysis)&#xD;
&#xD;
      Pulsitile Arterial Tonometry (PAT) Protocol Calf Blood Flow in Reactive Hyperemia (CBF-RH) -&#xD;
      venous occlusion plethysmography Evaluation of Forearm-Mediated Dilation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2021</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMD (% Change)</measure>
    <time_frame>FMD was assessed on the morning of day 7, after 6 days of being on either a high salt diet or a low salt diet.</time_frame>
    <description>The primary analysis will involve a non-parametric, paired, Signed Rank test of flow mediated dilation (FMD) between all subjects (POTS &amp; control subjects) on the high sodium diet vs low sodium diet</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Postural Tachycardia Syndrome (POTS)</condition>
  <arm_group>
    <arm_group_label>High Sodium - POTS &amp; Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), &amp; evaluation of forearm-mediated dilation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Sodium Diet (POTS &amp; Controls)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.&#xD;
Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), &amp; evaluation of forearm-mediated dilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulsitile Arterial Tonometry (PAT) Protocol</intervention_name>
    <description>A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).&#xD;
RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.&#xD;
Continuous recording of pulsatile blood volume responses from both hands will be initiated.&#xD;
After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped.</description>
    <arm_group_label>High Sodium - POTS &amp; Controls</arm_group_label>
    <arm_group_label>Low Sodium Diet (POTS &amp; Controls)</arm_group_label>
    <other_name>EndoPat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Calf Blood Flow in Reactive Hyperemia (CBF-RH)</intervention_name>
    <description>Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed</description>
    <arm_group_label>High Sodium - POTS &amp; Controls</arm_group_label>
    <arm_group_label>Low Sodium Diet (POTS &amp; Controls)</arm_group_label>
    <other_name>Hokansan strain guage venous plethysmography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evaluation of Forearm-Mediated Dilation</intervention_name>
    <description>The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.</description>
    <arm_group_label>High Sodium - POTS &amp; Controls</arm_group_label>
    <arm_group_label>Low Sodium Diet (POTS &amp; Controls)</arm_group_label>
    <other_name>Ultrasound</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be enrolled in the parent study &quot;Dietary Salt in Postural Tachcyardia&#xD;
             Syndrome&quot; funded by R01 HL102387 Postural Tachycardia Syndrome&#xD;
&#xD;
          -  Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction&#xD;
             Center&#xD;
&#xD;
          -  Subjects will be enrolled in the parent study &quot;Dietary Salt in Postural Tachcyardia&#xD;
             Syndrome&quot; funded by R01 HL102387&#xD;
&#xD;
          -  Postural Tachycardia Syndrome&#xD;
&#xD;
          -  Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction&#xD;
             Center&#xD;
&#xD;
          -  Increase in heart rate â‰¥30 beats/min with position change from supine to standing (10&#xD;
             minutes)&#xD;
&#xD;
          -  Chronic symptoms consistent with POTS that are worse when upright and get better with&#xD;
             recumbence Control Subjects&#xD;
&#xD;
          -  Healthy, non-obese, non-smokers without orthostatic tachycardia&#xD;
&#xD;
          -  Selected to match profiles of POTS patients (gender, age)&#xD;
&#xD;
          -  Not using vasoactive medication&#xD;
&#xD;
          -  Age between 18-60 years&#xD;
&#xD;
          -  Male and female subjects are eligible.&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overt cause for postural tachycardia (such as acute dehydration)&#xD;
&#xD;
          -  Inability to give, or withdrawal of, informed consent&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Other factors which in the investigator's opinion would prevent the subject from&#xD;
             completing the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satish R Raj, MD MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 1997 Nov 18;96(10):3378-83.</citation>
    <PMID>9396430</PMID>
  </reference>
  <reference>
    <citation>Al Suwaidi J, Higano ST, Holmes DR Jr, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol. 2001 May;37(6):1523-8.</citation>
    <PMID>11345360</PMID>
  </reference>
  <reference>
    <citation>BÃ¶ger RH, Bode-BÃ¶ger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998 Nov 3;98(18):1842-7.</citation>
    <PMID>9799202</PMID>
  </reference>
  <reference>
    <citation>Mangin EL Jr, Kugiyama K, Nguy JH, Kerns SA, Henry PD. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res. 1993 Jan;72(1):161-6.</citation>
    <PMID>8417838</PMID>
  </reference>
  <reference>
    <citation>Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovych V, Fellin R, Malinski T. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability. Circulation. 2000 Mar 21;101(11):1261-6.</citation>
    <PMID>10725285</PMID>
  </reference>
  <reference>
    <citation>Landmesser U, Merten R, Spiekermann S, BÃ¼ttner K, Drexler H, Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2000 May 16;101(19):2264-70.</citation>
    <PMID>10811593</PMID>
  </reference>
  <reference>
    <citation>Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO 3rd. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995 Apr;95(4):1747-55.</citation>
    <PMID>7706483</PMID>
  </reference>
  <reference>
    <citation>Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR, Sacks FM, Smith SC Jr, Vafiadis DK, Van Horn LV. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation. 2011 Mar 15;123(10):1138-43. doi: 10.1161/CIR.0b013e31820d0793. Epub 2011 Jan 13.</citation>
    <PMID>21233236</PMID>
  </reference>
  <reference>
    <citation>Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev. 2005 Apr;85(2):679-715. Review.</citation>
    <PMID>15788708</PMID>
  </reference>
  <reference>
    <citation>MENEELY GR, BALL CO. Experimental epidemiology of chronic sodium chloride toxicity and the protective effect of potassium chloride. Am J Med. 1958 Nov;25(5):713-25.</citation>
    <PMID>13582981</PMID>
  </reference>
  <reference>
    <citation>Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009 Nov 24;339:b4567. doi: 10.1136/bmj.b4567. Review.</citation>
    <PMID>19934192</PMID>
  </reference>
  <reference>
    <citation>Dishy V, Sofowora GG, Imamura H, Nishimi Y, Xie HG, Wood AJ, Stein CM. Nitric oxide production decreases after salt loading but is not related to blood pressure changes or nitric oxide-mediated vascular responses. J Hypertens. 2003 Jan;21(1):153-7.</citation>
    <PMID>12544447</PMID>
  </reference>
  <reference>
    <citation>Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension : modulation of nitric oxide synthesis by salt intake. Circulation. 2000 Feb 29;101(8):856-61.</citation>
    <PMID>10694524</PMID>
  </reference>
  <reference>
    <citation>Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas RH, Udelson JE. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003 Jul;146(1):168-74.</citation>
    <PMID>12851627</PMID>
  </reference>
  <reference>
    <citation>Rozanski A, Qureshi E, Bauman M, Reed G, Pillar G, Diamond GA. Peripheral arterial responses to treadmill exercise among healthy subjects and atherosclerotic patients. Circulation. 2001 Apr 24;103(16):2084-9.</citation>
    <PMID>11319199</PMID>
  </reference>
  <reference>
    <citation>Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Creager MA. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol. 1996 Apr;270(4 Pt 2):H1435-40.</citation>
    <PMID>8967386</PMID>
  </reference>
  <reference>
    <citation>Dakak N, Husain S, Mulcahy D, Andrews NP, Panza JA, Waclawiw M, Schenke W, Quyyumi AA. Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction. Hypertension. 1998 Jul;32(1):9-15.</citation>
    <PMID>9674631</PMID>
  </reference>
  <reference>
    <citation>Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Kajiyama G, Oshima T. A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol. 2001 Jan 1;87(1):121-5, A9.</citation>
    <PMID>11137850</PMID>
  </reference>
  <reference>
    <citation>Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002 Jan 15;105(2):213-7.</citation>
    <PMID>11790703</PMID>
  </reference>
  <reference>
    <citation>Noon JP, Haynes WG, Webb DJ, Shore AC. Local inhibition of nitric oxide generation in man reduces blood flow in finger pulp but not in hand dorsum skin. J Physiol. 1996 Jan 15;490 ( Pt 2):501-8.</citation>
    <PMID>8821146</PMID>
  </reference>
  <reference>
    <citation>Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol (1985). 2006 Aug;101(2):545-8. Epub 2006 Apr 13.</citation>
    <PMID>16614356</PMID>
  </reference>
  <reference>
    <citation>Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H2-12. doi: 10.1152/ajpheart.00471.2010. Epub 2010 Oct 15. Review.</citation>
    <PMID>20952670</PMID>
  </reference>
  <reference>
    <citation>Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005 Jan;23(1):7-17. Review.</citation>
    <PMID>15643116</PMID>
  </reference>
  <reference>
    <citation>Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004 Dec 7;44(11):2137-41.</citation>
    <PMID>15582310</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension--United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011 Feb 4;60(4):103-8.</citation>
    <PMID>21293325</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <results_first_submitted>November 8, 2021</results_first_submitted>
  <results_first_submitted_qc>December 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2022</results_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Alfredo Gamboa</investigator_full_name>
    <investigator_title>Research Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>POTS</keyword>
  <keyword>endothelial function</keyword>
  <keyword>high salt vs low salt diet</keyword>
  <keyword>PAT protocol</keyword>
  <keyword>Calf blood flow</keyword>
  <keyword>forearm mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT01550315/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Sodium First- POTS</title>
          <description>POTS patients received a high salt diet (300 mEq/day) for 6 days in a randomized crossover design and two weeks after, were crossover to receive a low high diet for 6 days</description>
        </group>
        <group group_id="P2">
          <title>Low Sodium Diet First-POTS</title>
          <description>POTS patients received a low salt diet (10 mEq/day) for 6 days in a randomized crossover design, and two weeks later received a high salt diet.</description>
        </group>
        <group group_id="P3">
          <title>High Sodium First- Controls</title>
          <description>Healthy Controls received a high salt diet (300 mEq/day) for 6 days in a randomized crossover design and two weeks after, received a low high diet for 6 days</description>
        </group>
        <group group_id="P4">
          <title>Low Sodium First-Controls</title>
          <description>Healthy Controls received a low salt diet (10 mEq/day) for 6 days in a randomized crossover design, and two weeks later received a high salt diet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study POTS</title>
          <description>POTS patients received high sodium diet for 4-5 days prior to study day. Then received either a high sodium diet (300 mEq/day) diet for 6 days, then after 2 weeks were randomized in a crossover design to receive a low sodium diet (10 mEq/day) diet for 6 days, or viceversa (first low then high salt diet). All POTS patients received both diets.&#xD;
Evaluation of Forearm-Mediated Dilation: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.</description>
        </group>
        <group group_id="B2">
          <title>All Study Controls</title>
          <description>Healthy controls received high sodium diet for 4-5 days prior to study day. Then received either a high sodium diet (300 mEq/day) diet for 6 days, then after 2 weeks were randomized in a crossover design to receive a low sodium diet (10 mEq/day) diet for 6 days, or viceversa (first low then high salt diet). All healthy controls received both diets.&#xD;
Evaluation of Forearm-Mediated Dilation: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="8"/>
                    <measurement group_id="B2" value="31" spread="6"/>
                    <measurement group_id="B3" value="33" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="00"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FMD (% Change)</title>
        <description>The primary analysis will involve a non-parametric, paired, Signed Rank test of flow mediated dilation (FMD) between all subjects (POTS &amp; control subjects) on the high sodium diet vs low sodium diet</description>
        <time_frame>FMD was assessed on the morning of day 7, after 6 days of being on either a high salt diet or a low salt diet.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Sodium POTS</title>
            <description>POTS patients received a high sodium diet for 4-5 days prior to study day. After enrollment, they received a high salt diet (300 mEq/day) diet for 6 days in a randomized crossover design.&#xD;
Evaluation of Forearm-Mediated Dilation: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.</description>
          </group>
          <group group_id="O2">
            <title>Low Sodium Diet POTS</title>
            <description>POTS patients received a high sodium diet for 4-5 days prior to study day. After enrollment, they received either a low-sodium (LS; 10 mEq/day) diet for 6 days.&#xD;
Evaluation of Forearm-Mediated Dilation: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.</description>
          </group>
          <group group_id="O3">
            <title>High Sodium Controls</title>
            <description>Healthy controls received a high sodium diet for 4-5 days prior to study day. After enrollment, they received a high salt diet (300 mEq/day) diet for 6 days in a randomized crossover design.&#xD;
Evaluation of Forearm-Mediated Dilation: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.</description>
          </group>
          <group group_id="O4">
            <title>Low Sodium Controls</title>
            <description>Healthy controls received a high sodium diet for 4-5 days prior to study day. After enrollment, they received either a low-sodium (LS; 10 mEq/day) diet for 6 days.&#xD;
Evaluation of Forearm-Mediated Dilation: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.</description>
          </group>
        </group_list>
        <measure>
          <title>FMD (% Change)</title>
          <description>The primary analysis will involve a non-parametric, paired, Signed Rank test of flow mediated dilation (FMD) between all subjects (POTS &amp; control subjects) on the high sodium diet vs low sodium diet</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.75" spread="43.77"/>
                    <measurement group_id="O2" value="11.65" spread="4.93"/>
                    <measurement group_id="O3" value="11.43" spread="4.26"/>
                    <measurement group_id="O4" value="12.75" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected while the participants were receiving the study diets. For all participants (POTS and Controls), it involved at least 22 days: 4 days prior to randomization, 6 days in the first diet, the first study day, 2 weeks of washout, 6 days in the second diet, and the last study day.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Sodium - POTS</title>
          <description>POTS patients received a high salt diet (300 mEq/day) for 6 days in a randomized crossover design</description>
        </group>
        <group group_id="E2">
          <title>Low Sodium Diet - POTS</title>
          <description>POTS patients received a low salt diet (10 mEq/day) for 6 days in a randomized crossover design</description>
        </group>
        <group group_id="E3">
          <title>High Sodium - Controls</title>
          <description>Healthy controls received a high salt diet (300 mEq/day) for 6 days in a randomized crossover design</description>
        </group>
        <group group_id="E4">
          <title>Low Sodium - Controls</title>
          <description>Healthy controls received a low salt diet (10 mEq/day) for 6 days in a randomized crossover design</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alfredo Gamboa</name_or_title>
      <organization>Vanderbilt Universtiy</organization>
      <phone>6158751003</phone>
      <email>alfredo.gamboa@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

